Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma

PROVIDER: PRJNA684966 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other
	SRR13279930.fastq.gz	Fastqsanger.gz
	SRR13279930_1.fastq.gz	Fastqsanger.gz
	SRR13279930_2.fastq.gz	Fastqsanger.gz
	SRR13279931.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 193

Similar Datasets

Homo sapiens

Project description:A compendium of myeloma associated chromosomal copy number abnormalities and their prognostic value

| PRJNA126129 | ENA

Homo sapiens

Project description:Prognostic significance of copy-number alterations in multiple myeloma

| PRJNA110893 | ENA

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tags (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD038437 | Pride

Proteogenomic landscape of multiple myeloma

Project description:Multiple myeloma is a plasma cell malignancy of the bone marrow. Despite therapeutic advances, multiple myeloma remains incurable and better risk stratification as well as new therapies are therefore highly needed. The proteome of multiple myeloma has not been systematically assessed before and holds the potential to uncover additional insight into disease biology and improved prognostic models. Here, we provide a comprehensive multi-omics analysis including deep tandem mass tag (TMT)-based quantitative global (phospho)proteomics, RNA sequencing and nanopore DNA sequencing of 138 primary patient-derived plasma cell malignancies encompassing treatment-naive multiple myeloma patients treated in clinical trials, plasma cell leukemia, and the premalignancy monoclonal gammopathy of undetermined significance (MGUS), as well as healthy controls. We found that the (phospho)proteome of malignant plasma cells is highly deregulated as compared to healthy plasma cells and is both defined by chromosomal alterations and extensive post-transcriptional regulation. A protein signature was identified that is associated with aggressive disease and more predictive for outcome than cytogenetic-based risk assessment in newly diagnosed multiple myeloma. Integration with functional genetics and single-cell sequencing revealed generally and genetic subtype-specific deregulated proteins and pathways in plasma cell malignancies that include novel potential targets for (immuno)therapies. These findings provide new insights in the biology of multiple myeloma and will be a unique resource for investigating new therapeutic approaches.

2024-07-09 | PXD043580 | Pride

Array comparative genomic hybridization of canine follicular lymphoma (cFL) and canine marginal zone lymphoma (cMZL)

Project description:The aim of this work was to identify the copy number aberrations (CNAs) by high-resolution array comparative genomic hybridization (aCGH) on 7 dogs with newly diagnosed FL and 5 dogs with newly diagnosed MZL.

2020-06-30 | GSE131618 | GEO

Project description:Sequencing of newly diagnosed multiple myeloma patients

| PRJNA826654 | ENA

Gene Expression profiling of Multiple Myeloma

Project description:Gene Expression profiling of 170 newly diagnosed Multiple Myeloma patients Gene Expression profiling of Multiple Myeloma

2012-09-10 | GSE39754 | GEO

Array comparative genomic hybridization of canine diffuse large B-cell lymphoma (cDLBCL)

Project description:The aim of this work was to identify copy number variations (CNVs) by high-resolution array comparative genomic hybridization (aCGH) on 50 dogs with newly diagnosed DLBCL.

2019-05-01 | GSE113258 | GEO

Expression data of newly diagnosed multiple myeloma and extramedullary myeloma

Project description:Expression data of newly diagnosed multiple myeloma and extramedullary myeloma

| PRJNA622259 | ENA

Copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia

Project description:Large but not small copy-number alterations correlate to high-risk genomic aberrations and survival in chronic lymphocytic leukemia: a high-resolution genomic screening of newly diagnosed patients. Single nucleotide polymorphism (SNP)-arrays allow simultaneous detection of copy-number aberrations (CNAs) and copy-number neutral loss-of-heterozygosity (CNN-LOH). In this study we investigated the presence of CNAs and CNN-LOH in newly diagnosed CLL samples from a Swedish chronic lymphocytic leukemia (CLL) cohort. In this study we could detect the known recurrent aberrations in CLL (i.e. deletions of 13q, 11q, 17p and trisomy 12). We also detected other both large and small CNAs which were mostly non-recurrent. CNN-LOH was detected on chromosome 13q in patients that carried homozygous deletion of 13q.

2009-11-23 | GSE16406 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data